FDA OGD guidance
This article was originally published in The Tan Sheet
Executive Summary
Office of Generic Drugs will withdraw at least 24 drug specific bioequivalence guidances that "no longer reflect the current thinking of the agency," FDA announces in the July 8 Federal Register. The agency also is requesting public comment on topics for future guidance development regarding generic drugs. The 24 guidances to be withdrawn are not specified in the notice